1999 Fiscal Year Final Research Report Summary
Effect of chemokine gene transfection on acquistion of whole body tumor immunity
| Project/Area Number |
10672156
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
応用薬理学・医療系薬学
|
|---|
| Research Institution | Kyoritsu University of Pharmacy |
|---|
Principal Investigator |
NAKASHIMA Emi Kyoritsu College of Pharmacy, Faculty of Pharmaceutical Sciences, Professor (90115254)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
IIZASA Hisashi Kyoritsu College of Pharmacy, Faculty of Pharmaceutical Sciences, Research Associate (80306662)
HATTORI Kenji Kyoritsu College of Pharmacy, Faculty of Pharmaceutical Sciences, Research Associate (90306663)
TSUJI Akira Kanazawa University, Faculty of Pharmaceutical Sciences, Professor (10019664)
|
|---|
| Project Period (FY) |
1998 – 1999
|
| Keywords | TUMOR IMMUNITY / BIOLOGICAL RESPONSE MODIFIER / GENE TRNSFECTION / CHEMOKINE / INDOMETHACIN / TUMOR / CYTOKINE / CONCOMITANT THERAPY |
|---|
| Research Abstract |
The immune cells, such as T lymphocyte and the natural killer cell, act an important role in tumor regression. We studied monocyte chemotactic protein-1(MCP-1) and macrophage inflammatory protein- la(MIP-1a) those are chemotactic factor of memory T lymphocyte and the chemokine acting to monocyte which is the precursor cell of the macrophage, respectively.
We have already reported that these genes-transfected tumor cells induced apoptosis of the transplanted tumor cells. Especially, MTP- la gene-transfected tumor were rejected by the mouse of about 30%. Here, we examined the influence on the host immune response by using the Colon26clone20 colon cancer cells (hereafter, C20) introduced the gene of MCAF/MCP-1, and the synergistic administration of biological response modifier (BRM) were investigated. When both indomethacin and BRM were administered to the mouse harbored the carcinoma cell, the number of mice that rejected, and a remarkable antitumor effect was obtained. This effect was not observed in the SCID mouse that did not have T cell and B cell. Inoculated C20 cells again were also rejected. It was confirmed that the mouse obtained the tumor immunity. The antitumor effect of synergistic administration of indomethacin and BRM tended to be weakened in the mouse transplanted the MCAF/MCP-1 gene-transfected C20. For the tumor that decreases host immunity, MCAF/MCP-1 urges the macrophage permeation into the tumor, however, the activation of enough macrophage were not induced. Moreover, it was shown that the synergistic antitumor effects were obtained by using together with the medicine that adjusted the macrophage.
|
-
-
-
-
[Presentation] 剤形の形の意味2000
Author(s)
中島恵美
Organizer
第3回創薬における医薬品情報
Place of Presentation
東京
Year and Date
20000100
Description
「研究成果報告書概要(和文)」より
-
-
-
[Presentation] 薬の上手な使い方1999
Author(s)
中島恵美
Organizer
第25回日本医学会総会
Place of Presentation
東京
Year and Date
19990400
Description
「研究成果報告書概要(和文)」より
-
-
-
-
-
[Book] 医学の歩み1999
Author(s)
中島恵美、飯笹久
Total Pages
5
Publisher
医歯薬出版
Description
「研究成果報告書概要(和文)」より
